Oral HDAC inhibitor tucidinostat in sufferers with relapsed or refractory peripheral T-mobile lymphoma: phase IIb success In summary, although the medical influence of tucidinostat for the remedy of PTCL has actually been elucidated, additional mechanistic examine and biomarker identification for patient stratification should be illustrated in the future. There are https://waltc322nzk5.ambien-blog.com/profile